BioLife Solutions Key Fundamental And Technical Indicators

Stocks . USA . 
Stock . BioLife Solutions
BLFS Stock  USD 21.57  0.02  0.09%   
BioLife Solutions' ratios page distills the financial statements into the key efficiency, leverage, and profitability metrics. BioLife Solutions trades at a price-to-earnings ratio of 173.59. The current ratio is 3.55, showing the ability to cover short-term obligations. As of now, RSI for BioLife Solutions stands at 52, indicating neutral momentum. Momentum at the midline is a blank slate - upcoming volume and price action will likely determine the next leg.
Momentum
 Impartial
52
OversoldOverbought
Market data as of the 6th of May shows BioLife Solutions priced at 21.57 per share. Measured indicators report Standard Deviation of 3.11, risk adjusted performance of -0.0032, and Mean Deviation of 2.36. The model examines historical data series to identify measurable trend characteristics. Technical levels are measured against peer distributions.
Cycles Operators Shifting Impulse Patterns Depth Overlaps Statistics Volatility Volume
Analyzing historical trends in BioLife Solutions' income statement and balance sheet accounts supports evaluation. Fundamental drivers influencing BioLife Solutions' valuation are shown below:
BioLife Solutions does not currently have any fundamental trend indicators for analysis. See Equity Screeners for additional filtering and comparison across instruments. The framework supports screening across sectors, industries, and market segments.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

BioLife Solutions' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

 = 

Operating Income

Revenue

X

100

Current BioLife Solutions Operating Margin TTM
    
  -0.0032  
Most of BioLife Solutions' key ratios, such as Operating Margin TTM, are part of a framework for finding mispriced stocks. This analysis gives context for investors weighing whether BioLife Solutions' current price level is fair. Cross-checking multiple valuation measures reduces the risk of drawing conclusions from one metric's blind spots. BioLife Solutions currently trades at a P/E of 173.59, which provides additional valuation context. Weighing both data-based ratios and softer factors when judging BioLife Solutions strengthens the aggregate assessment. A price-to-book ratio of 2.79 helps frame the market's assessment of BioLife Solutions' asset base.
Competition

BioLife Solutions Fundamental Drivers Relationships

Main Technical Indicators as of May 6, 2026

Cycle Indicators
Math Operators
Math Transform
Momentum Indicators
Overlap Studies
Pattern Recognition
Price Transform
Statistic Functions
Volatility Indicators
Volume Indicators
Risk Adjusted Performance-0.0032
Market Risk Adjusted Performance-0.02
Mean Deviation2.36
Coefficient Of Variation-9,674
Standard Deviation3.11
Variance9.66
Information Ratio-0.01
Jensen Alpha-0.02
Total Risk Alpha-0.0041
Treynor Ratio-0.03
Maximum Drawdown18.09
Value At Risk-5.39
Potential Upside3.92
Skewness-0.68
Kurtosis1.42

Daily Market Strength Indicators

For investors tracking BioLife Solutions, market strength indicators offer quantitative evaluation of stock behavior. When Rate of Change diverges from price direction, it often signals weakening momentum before a visible reversal in BioLife Solutions.
Accumulation Distribution9.0E-4
Daily Balance Of Power1.0
Rate Of Daily Change1.0
Day Median Price21.56
Day Typical Price21.56
Market Facilitation Index0.02
Price Action Indicator0.02
Period Momentum Indicator0.02
Relative Strength Index52.22

Basic Forecasting Models

Analyzing BioLife Solutions' price movement through moving averages at different time horizons reveals whether short-term momentum aligns with the longer-term trend. Touches of the upper or lower band in BioLife Solutions' chart signal overbought or oversold conditions.
Naive Prediction
Simple Exponential Smoothing
Double Exponential Smoothing
Triple Exponential Smoothing
Simple Regression
Polynomial Regression
Simple Moving Average
4 Period Moving Average
8 Period Moving Average
20 Period Moving Average

BioLife Solutions Related Equities

Checking BioLife Solutions against related firms within the Health Care space reveals where the stock stands among peers. Checking BioLife Solutions against peers on P/E, margins, and return on equity helps put its position in context.
 Risk & Return  Correlation

Operating Margin TTM Peer Comparison

Comparing BioLife Solutions to its peers on Operating Margin TTM is a standard technique for assessing relative investment value. This comparison reveals whether BioLife Solutions' Operating Margin TTM is in line with or diverges from that of direct competitors.
BioLife Solutions is currently under evaluation in operating margin ttm relative to competitors.

Important Fundamentals

Return On Equity TTM-0.0337
Return On Asset TTM-0.0017
Profit Margin TTM-0.0478
Operating Margin TTM-0.0032
Current Valuation964.75 M
Shares Outstanding48.86 M
Shares Owned By Insiders2.38 %
Shares Owned By Institutions97.62 %
Number Of Shares Shorted3.33 M
Price To Earnings TTM173.59 X
Price To Book TTM2.79 X
Price To Sales TTM10.71 X
Revenue TTM96.21 M
Gross Profit TTM62.12 M
EBITDA TTM-9.38 M
Net Income TTM-4.59 M
Cash And Equivalents TTM46.55 M
Cash Per Share TTM1.09 X
Total Debt TTM17.9 M
Debt To Equity TTM0.06 %
Current Ratio TTM3.55 X
Book Value Per Share TTM7.72 X
Cash Flow From Operations TTM20.11 M
Short Ratio TTM9.05 X
Earnings Per Share-0.25 X
Price To Earnings To Growth15.09 X
Target Price32.4
Number Of Employees155
Trailing Beta1.97
Market Capitalization TTM1.03 B
Total Asset TTM405.88 M
Retained Earnings TTM-339.7 M
Working Capital TTM113.58 M
Current Asset TTM6.97 M
Current Liabilities TTM1.73 M
Net Asset405.88 M

Financial Metrics, Fundamentals & Methodology

A closer look at BioLife Solutions shows how capital structure and profitability shape financial flexibility. Balance-sheet composition shapes financial flexibility and solvency risk. In recent filings, BioLife Solutions reported revenue of 96.21 million, EPS loss of 0.25, negative operating margin of 0.32% as of the latest reporting period.

BioLife Solutions analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Statement-level metrics reflect company-reported GAAP or IFRS formats for the relevant filing period.

Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.